The Association Between Myocardial Infarction and Intravitreal Bevacizumab Injection

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Mar 30

PMID 29595656

Citations 4

Authors

Jin-Woo Kwon

Donghyun Jee

Tae Yoon La

Affiliations

Soon will be listed here.

Abstract

To evaluate the risk of myocardial infarction (MI) after receiving intravitreal bevacizumab (IVB) injection. We retrospectively reviewed the charts of patients who had received IVB injection in 2016, and grouped them according to whether they received the injection for age-related macular degeneration (AMD), diabetes-related complications, or retinal vein occlusion (RVO). We then investigated the prevalence of MI within 2 months after IVB injection and analyzed the possible association of IVB with MI. During 2016, 724 patients were enrolled and received a total of 1870 IVB injections. Seven patients were diagnosed with MI within 2 months after receiving an IVB injection. Of 274 patients with AMD, 2 were diagnosed with MI; of 311 patients with diabetes-related complications, 3 were diagnosed with MI; and of 139 patients with RVO, 2 were diagnosed with MI (P = 0.785). All MIs occurred between 3 days and 3 weeks after IVB injection (mean = 14.00 ± 6.45 days). The MIs after receiving IVB were associated with previous history of MI or cerebrovascular infarction in multivariate logistic regression analysis (P = 0.005). There was no significant difference in MI prevalence after IVB injection according to the reason for receiving the injection. However, care should be taken when administering IVB injections, especially to patients with risk factors such as history of MI or cerebrovascular infarction.

Citing Articles

Intravitreal Injection Therapy: Current Techniques and Supplemental Services.

Lam L, Mehta S, Lad E, Emerson G, Jumper J, Awh C J Vitreoretin Dis. 2023; 5(5):438-447.

PMID: 37008713 PMC: 9976140. DOI: 10.1177/24741264211028441.

Human Platelets Take up Anti-VEGF Agents.

Sobolewska B, Fehrenbacher B, Munzer P, Kalbacher H, Geue S, Stellos K J Ophthalmol. 2021; 2021:8811672.

PMID: 34221496 PMC: 8219439. DOI: 10.1155/2021/8811672.

Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere) in patients with neovascular age-related macular degeneration.

Benisek D, Manzitti J, Scorsetti D, Rousselot Ascarza A, Ascarza A, Gomez Rancano D Exp Ther Med. 2020; 20(6):162.

PMID: 33093900 PMC: 7571337. DOI: 10.3892/etm.2020.9291.

Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better.

Usui-Ouchi A, Friedlander M J Clin Invest. 2019; 129(8):3032-3034.

PMID: 31232702 PMC: 6668662. DOI: 10.1172/JCI129862.

References

Avery R, Castellarin A, Steinle N, Dhoot D, Pieramici D, See R . Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014; 98(12):1636-41. PMC: 4251300. DOI: 10.1136/bjophthalmol-2014-305252. View

Silva P, Sun J, Aiello L . Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol. 2009; 24(2):93-9. DOI: 10.1080/08820530902800355. View

Campbell R, Gill S, Bronskill S, Paterson J, Whitehead M, Bell C . Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ. 2012; 345:e4203. PMC: 3389519. DOI: 10.1136/bmj.e4203. View

Domigan C, Warren C, Antanesian V, Happel K, Ziyad S, Lee S . Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy. J Cell Sci. 2015; 128(12):2236-48. PMC: 4487014. DOI: 10.1242/jcs.163774. View

Mikacic I, Bosnar D . Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Drug Saf. 2016; 39(6):517-41. DOI: 10.1007/s40264-016-0408-y. View

Vinores S, McGehee R, Lee A, Gadegbeku C, Campochiaro P . Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats. J Histochem Cytochem. 1990; 38(9):1341-52. DOI: 10.1177/38.9.2117624. View

Kriechbaum K, Prager F, Geitzenauer W, Benesch T, Schutze C, Simader C . Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Ophthalmology. 2009; 116(12):2415-21. DOI: 10.1016/j.ophtha.2009.05.001. View

Jee D, Zako M, La T . Serum D-dimer levels to evaluate the risk for arterial thromboembolism after intravitreal injection of bevacizumab and ranibizumab. J Ocul Pharmacol Ther. 2014; 31(1):32-6. DOI: 10.1089/jop.2013.0234. View

Boyer D, Heier J, Brown D, Francom S, Ianchulev T, Rubio R . A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(9):1731-9. DOI: 10.1016/j.ophtha.2009.05.024. View

10.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

11.

Schmid M, Bachmann L, Fas L, Kessels A, Job O, Thiel M . Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2014; 99(2):141-6. DOI: 10.1136/bjophthalmol-2014-305149. View

12.

Al-Rubeaan K, Abu El-Asrar A, Youssef A, Subhani S, Ahmad N, Al-Sharqawi A . Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. Acta Ophthalmol. 2014; 93(2):e140-7. DOI: 10.1111/aos.12532. View

13.

Carneiro A, Costa R, Falcao M, Barthelmes D, Mendonca L, Fonseca S . Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2011; 90(1):e25-30. DOI: 10.1111/j.1755-3768.2011.02240.x. View

14.

Stitt A, Curtis T, Chen M, Medina R, Mckay G, Jenkins A . The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2015; 51:156-86. DOI: 10.1016/j.preteyeres.2015.08.001. View

15.

Parikh R, Traband A, Kolomeyer A, VanderBeek B, Kim B, Maguire A . Intravitreal Bevacizumab for the Treatment of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy. Am J Ophthalmol. 2017; 176:194-202. PMC: 5376507. DOI: 10.1016/j.ajo.2017.01.010. View

16.

Thulliez M, Angoulvant D, Le Lez M, Jonville-Bera A, Pisella P, Gueyffier F . Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014; 132(11):1317-26. DOI: 10.1001/jamaophthalmol.2014.2333. View

17.

Olsen T, Feng X, Wabner K, Csaky K, Pambuccian S, Cameron J . Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest Ophthalmol Vis Sci. 2011; 52(7):4749-56. PMC: 3175963. DOI: 10.1167/iovs.10-6291. View

18.

Penman A, Hancock H, Papavasileiou E, James M, Idowu O, Riche D . Risk Factors for Proliferative Diabetic Retinopathy in African Americans with Type 2 Diabetes. Ophthalmic Epidemiol. 2016; 23(2):88-93. PMC: 4851860. DOI: 10.3109/09286586.2015.1119287. View

19.

Mintz-Hittner H, Kennedy K, Chuang A . Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7):603-15. PMC: 3119530. DOI: 10.1056/NEJMoa1007374. View

20.

Zechariah A, ElAli A, Doeppner T, Jin F, Hasan M, Helfrich I . Vascular endothelial growth factor promotes pericyte coverage of brain capillaries, improves cerebral blood flow during subsequent focal cerebral ischemia, and preserves the metabolic penumbra. Stroke. 2013; 44(6):1690-7. DOI: 10.1161/STROKEAHA.111.000240. View